MabThera/Rituxan

Sandoz joins Europe's MabThera biosimilar push

Novartis' Sandoz unit has become the second company to claim approval in Europe for a biosimilar version of Roche's blockbuster immunotherapy drug MabThera. ... MabThera is celebrating its 20th year on the market this year, and has been a massive earner

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

The CHMP also backed three biosimilars of Roche's Rituxan (rituximab) developed by Celltrion namely Blitzima, Tuxella and Ritemvia.

WHO pilots scheme to make biosimilars available to poorer countries

Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin. ... In the latest move the WHO says it will focus on biosimilar medicines, starting with Roche's widely-used cancer drugs MabThera/Rituxan (rituximab) and

A new decade of disruption: meeting the biosimilar challgenge

As the dust settles on the first ten years of disruption, the spotlight is now on the future as more leading MAbs, including Humira (adalimumab), MabThera (rituximab), Avastin (bevacizumab) and Lucentis

Mylan deal with Roche clears path to biosimilar Herceptin launch

Aside from Herceptin, and biosimilars of Roche's Avastin (bevacizumab) and Rituxan/MabThera (rituximab) are also starting to reach the market.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]